Session 7
The role of the immune system in ALCL
Chair: Olaf Merkel, MedUni Vienna/Vienna General Hospital, Austria
11.15 am – 12.00 pm
Plenary talk VI
Kinase-driven immune evasion program in ALCL revealed by glycoproteomics
Megan Lim, University of Pennsylvania, USA
12.00 – 12.20 pm
ALKATRAS ESR12
Mechanisms of immunogenicity in ALK+ ALCL
Adriana Petrazzuolo, Gustave Roussy Cancer Campus Paris, France
12.20 – 12.40 pm
ALKATRAS ESR11
CD4 T-cell response against ALK in patients with ALK+
Serena Stadler, University of Giessen, Germany
12.40 – 1.45 pm
Lunch Break

Session 8
Novel therapeutic approaches towards the treatment of lymphoma
Chair: Roberto Chiarle, Harvard Medical School, Boston, USA
1.45 – 2.30 pm
Plenary talk VII
MedUni Vienna Highlights: Clinical Management of B- and T-cell lymphomas
Ulrich Jäger, MedUni Vienna/Vienna General Hospital, Austria
2.30 – 2.50 pm
ALKATRAS ESR13
The ALK/ROS1/TRK inhibitor repotrectinib (TPX-0005), effectively reduces growth of ALK-driven neureoblastoma cells
Joanna Szydzik, University of Gothenburg, Sweden
2.50 – 3.10 pm
ALKATRAS ESR10
ALK vaccine enhances anti-PD1 therapeutic effect in NSCLC pre-clinical mouse models
Ines Mota, University of Torino, Italy
3.10 – 3.30 pm
ALKATRAS ESR14
Dissecting the immune-response and -escape of ALK driven T-cell lymphomas
Teresa Poggio, University of Frankfurt, Germany
3.30 – 4.00 pm
Coffee

Session 9
Mechanisms of T cell lymphomagenesis
Chair: Megan Lim, University of Pennsylvania, Philadelphia, USA
4.00 – 4.30 pm
Beauty driver mutations in JAK3-STAT3/5 form T cell neoplasms: How we model and explore targeting of them
Richard Moriggl, University of Veterinary Medicine, Vienna, Austria
4.30 – 4.50 pm
The gain-of-function STAT5BN642H mutation is a driver of immature or mature T cells
Tobias Suske, University of Veterinary Medicine Vienna, Austria
4.50 – 5.10 pm
ALKATRAS ESR9
An alternative concept for the cellular origin of anaplastic large cell lymphoma, ALK+ and ALK-
Mariantonia Costanza, Charité – Universitätsmedizin Berlin, Germany
5.10 pm
Wrap-up and close of meeting (ALKATRAS SAB)

Organising committee
Olaf Merkel, MedUni Vienna/Vienna General Hospital, Austria
Sandra Egger, MedUni Vienna/Vienna General Hospital, Austria
Lukas Anton, MedUni Vienna/Vienna General Hospital and University of Veterinary Medicine Vienna, Austria
Suzanne Turner, University of Cambridge, United Kingdom

Next meeting
11th ERIA meeting in 2020, Cambridge, United Kingdom

In Cooperation with

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 675712.

With the kind support of:
Thursday, 4th July

9.05 am
Arrival and Get-together

9.10 – 9.15 am
Introductory remarks
Markus Müller, Rector of the MedUni Vienna, Austria

9.15 – 10.00 am
Session 1 - Transcriptional regulation
Chair: Suzanne Turner, University of Cambridge, United Kingdom

10.00 – 10.30 am
Blockade of crizotinib-induced BCL2 elevation in ALK-driven malignancies
Estelle Espinos, INSERM Toulouse, France

10.30 – 11.00 am
Coffee

11.00 am – 11.45 pm
Plenary talk I
Chair: Lukas Kenner, MedUni Vienna/Vienna General Hospital, Austria

11.45 – 12.05 pm
ALKATRAS ESR1
Mutational landscape analysis in systemic ALCL identifies novel prognostic markers
Cosimo Lobello, CEITEC, Brno, Czech Republic

12.05 – 1.30 pm
Lunch Break

1.30 – 1.50 pm
Session 2 - Molecular markers
Chair: Lukas Kenner, MedUni Vienna/Vienna General Hospital, Austria

1.50 – 2.10 pm
ALKATRAS ESR5
The IL2 Receptor as a target of BATF3 AP-1 Module in ALCL
Huang-Chan Liang, MedUni Vienna/Vienna General Hospital, Austria

2.10 – 2.30 pm
ALKATRAS ESR4
Mechanisms of resistance to ALK inhibitors in ALCL
Ines Garces, MedUni Vienna/Vienna General Hospital, Austria

2.30 – 2.50 pm
ALKATRAS ESR15
Mechanisms of cell death in lymphoma (I)
Nina Prokoph, University of Cambridge, United Kingdom

2.50 – 3.10 pm
ALKATRAS ESR8
Mechanisms of cell death in lymphoma (II)
Huang-Chan Liang, MedUni Vienna/Vienna General Hospital, Austria

3.10 – 3.30 pm
Coffee

3.30 – 3.50 pm
ALKATRAS ESR9
Therapeutic modulation of autophagy in ALK+ ALCL
Domenico Sorrentino, Université Toulouse III Paul Sabatier, France

3.50 – 4.15 pm
Coffee

4.15 – 4.50 pm
Plenary talk II
Chair: Stephan Mathas, Charité and Max Delbrück Zentrum, Berlin, Germany

4.50 – 5.00 pm
Session 3 - Novel anti-apoptotic pathways in ALK+ ALCL
Chair: Roberto Chiarle, Harvard Medical School, Boston, USA

4.55 – 5.15 pm
Coffee

5.00 – 5.30 pm
Session 4 - Novel apoptotic pathways driven by NPM-ALK
Chair: Gerda Egger, MedUni Vienna/Vienna General Hospital, Austria

5.15 – 5.35 pm
Novel anti-apoptotic pathway driven by NPM-ALK
Gerda Egger, MedUni Vienna/Vienna General Hospital, Austria

5.35 – 5.50 pm
End and wrap-up of first day

Friday, 5th July

Session 6
Novel concepts for Lymphoma Therapy
Chair: Stephan Mathas, Charité and Max Delbrück Zentrum, Berlin, Germany

9.00 – 9.45 am
Plenary talk V
Where cancers come from and how we’ll make them disappear
Nigel Ewan, University of Cambridge, United Kingdom

9.45 – 10.15 am
Novel therapeutic approaches to eradicate persistor cells in Anaplastic Large Cell Lymphoma
Roberto Chiarle, Roberto Chiarle, Harvard Medical School, Boston, USA

10.15 – 10.35 am
ALKATRAS ESR6
The role of CEBPb and ALK-regulated miRNAs in ALK+ ALCL
Lara Mussolin and Federica Lovisa, University of Padua, Italy

10.35 – 11.15 am
Coffee

11.15 – 11.35 am
ALKATRAS ESR1
Where cancers come from and how we’ll make them disappear
Nigel Ewan, University of Cambridge, United Kingdom

11.35 – 11.55 am
ALKATRAS ESR2
Therapeutic modulation of autophagy in ALK+ ALCL
Domenico Sorrentino, Université Toulouse III Paul Sabatier, France

11.55 – 12.15 pm
ALKATRAS ESR3
End and wrap-up of first day

In Cooperation with ALKATRAS